Abivax (ABVX) reported a Q3 loss Monday of 2.10 euros ($2.47) per diluted share, widening from a loss of 0.87 euro a year earlier.
Total operating income for the three months ended Sept. 30 was 2 million euros, compared with 1.3 million euros a year earlier.
The company said that as of Sept. 30, it had cash and cash equivalents of 589.7 million euros, sufficient to fund cash flow requirements through Q4 2027.
Abivax shares were down 3.3% in recent premarket activity Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.